Alisertib Plus Paclitaxel Shows Promise for Patients With SCLC
Alisertib showed antitumor activity in preclinical in vivo small cell lung cancer (SCLC) models.
IASLC
Next-generation Sequencing of ctDNA Could Identify Resistance Mutations in NSCLC
Next-generation sequencing (NGS) of circulating DNA (ctDNA) could be used to identify emergent resistance mutations.
Genetic Alterations in NSCLC May Indicate Improved Response to Veliparib
Tumor genomes in tobacco users with non-small cell lung cancer (NSCLC) have genetic alterations that are associated with poor outcomes.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in IASLC 2016
Loading... 
Loading...